Analyse de série chronologique interrompue : Questions médicales fréquentes
Nom anglais: Interrupted Time Series Analysis
Descriptor UI:D065186
Tree Number:N06.850.520.450.500.912
Termes MeSH sélectionnés :
Network Meta-Analysis
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Analyse de série chronologique interrompue : Questions médicales les plus fréquentes",
"headline": "Analyse de série chronologique interrompue : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Analyse de série chronologique interrompue : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-04",
"dateModified": "2025-04-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Analyse de série chronologique interrompue"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Études épidémiologiques",
"url": "https://questionsmedicales.fr/mesh/D016021",
"about": {
"@type": "MedicalCondition",
"name": "Études épidémiologiques",
"code": {
"@type": "MedicalCode",
"code": "D016021",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N06.850.520.450.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Analyse de série chronologique interrompue",
"alternateName": "Interrupted Time Series Analysis",
"code": {
"@type": "MedicalCode",
"code": "D065186",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jürgen Rehm",
"url": "https://questionsmedicales.fr/author/J%C3%BCrgen%20Rehm",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Shannon Lange",
"url": "https://questionsmedicales.fr/author/Shannon%20Lange",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Y Li",
"url": "https://questionsmedicales.fr/author/Y%20Li",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Medical Virology and Viral Diseases of National Health Commission, National Institute of Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China."
}
},
{
"@type": "Person",
"name": "S C Yu",
"url": "https://questionsmedicales.fr/author/S%20C%20Yu",
"affiliation": {
"@type": "Organization",
"name": "Office of Epidemiology, Chinese Center for Disease Control and Prevention, Beijing 102206, China."
}
},
{
"@type": "Person",
"name": "C G Jin",
"url": "https://questionsmedicales.fr/author/C%20G%20Jin",
"affiliation": {
"@type": "Organization",
"name": "School of Social Development and Public Policy, Beijing Normal University, Beijing 100875, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Kenward-Roger-type corrections for inference methods of network meta-analysis and meta-regression.",
"datePublished": "2023-07-03",
"url": "https://questionsmedicales.fr/article/37399845",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jrsm.1652"
}
},
{
"@type": "ScholarlyArticle",
"name": "Diagnostic yield and safety of diagnostic techniques for pulmonary lesions: systematic review, meta-analysis and network meta-analysis.",
"datePublished": "2024-09-18",
"url": "https://questionsmedicales.fr/article/39293856",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1183/16000617.0046-2024"
}
},
{
"@type": "ScholarlyArticle",
"name": "Topical anti-inflammatory treatments for eczema: network meta-analysis.",
"datePublished": "2024-08-06",
"url": "https://questionsmedicales.fr/article/39105474",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD015064.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis.",
"datePublished": "2023-08-31",
"url": "https://questionsmedicales.fr/article/37650547",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD013730.pub2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Percutaneous coronary intervention in calcified stenoses: a protocol for a systematic review with meta-analysis, trial sequential analysis and network meta-analysis.",
"datePublished": "2022-09-02",
"url": "https://questionsmedicales.fr/article/36691161",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bmjopen-2022-063884"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Environnement et santé publique",
"item": "https://questionsmedicales.fr/mesh/D004778"
},
{
"@type": "ListItem",
"position": 3,
"name": "Santé publique",
"item": "https://questionsmedicales.fr/mesh/D011634"
},
{
"@type": "ListItem",
"position": 4,
"name": "Méthodes épidémiologiques",
"item": "https://questionsmedicales.fr/mesh/D004812"
},
{
"@type": "ListItem",
"position": 5,
"name": "Caractéristiques des études épidémiologiques",
"item": "https://questionsmedicales.fr/mesh/D016020"
},
{
"@type": "ListItem",
"position": 6,
"name": "Études épidémiologiques",
"item": "https://questionsmedicales.fr/mesh/D016021"
},
{
"@type": "ListItem",
"position": 7,
"name": "Analyse de série chronologique interrompue",
"item": "https://questionsmedicales.fr/mesh/D065186"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Analyse de série chronologique interrompue - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Analyse de série chronologique interrompue",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Analyse de série chronologique interrompue",
"description": "Comment identifier une série chronologique interrompue ?\nQuels outils sont utilisés pour l'analyse ?\nQuelles données sont nécessaires pour l'analyse ?\nComment évaluer la validité des résultats ?\nQuels biais peuvent affecter l'analyse ?",
"url": "https://questionsmedicales.fr/mesh/D065186?mesh_terms=Network+Meta-Analysis&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Analyse de série chronologique interrompue",
"description": "Quels symptômes peuvent être analysés ?\nComment les symptômes évoluent-ils après une intervention ?\nPeut-on mesurer des symptômes subjectifs ?\nLes symptômes sont-ils influencés par des facteurs externes ?\nComment les symptômes sont-ils collectés ?",
"url": "https://questionsmedicales.fr/mesh/D065186?mesh_terms=Network+Meta-Analysis&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Analyse de série chronologique interrompue",
"description": "Comment l'analyse aide-t-elle à la prévention ?\nQuels programmes peuvent être analysés ?\nComment mesurer l'impact d'une campagne de prévention ?\nQuels indicateurs de prévention sont pertinents ?\nPeut-on évaluer des interventions non médicales ?",
"url": "https://questionsmedicales.fr/mesh/D065186?mesh_terms=Network+Meta-Analysis&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Analyse de série chronologique interrompue",
"description": "Quels traitements peuvent être évalués par cette méthode ?\nComment mesurer l'efficacité d'un traitement ?\nPeut-on comparer plusieurs traitements ?\nQuels indicateurs de traitement sont utilisés ?\nComment les effets secondaires sont-ils pris en compte ?",
"url": "https://questionsmedicales.fr/mesh/D065186?mesh_terms=Network+Meta-Analysis&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Analyse de série chronologique interrompue",
"description": "Quelles complications peuvent être analysées ?\nComment les complications sont-elles mesurées ?\nLes complications sont-elles influencées par le temps ?\nPeut-on prédire des complications futures ?\nComment gérer les complications identifiées ?",
"url": "https://questionsmedicales.fr/mesh/D065186?mesh_terms=Network+Meta-Analysis&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Analyse de série chronologique interrompue",
"description": "Quels facteurs de risque peuvent être analysés ?\nComment les facteurs de risque influencent-ils les résultats ?\nPeut-on identifier des facteurs de risque modifiables ?\nComment les facteurs de risque sont-ils mesurés ?\nLes facteurs de risque changent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D065186?mesh_terms=Network+Meta-Analysis&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier une série chronologique interrompue ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il faut observer des changements significatifs dans les données après une intervention."
}
},
{
"@type": "Question",
"name": "Quels outils sont utilisés pour l'analyse ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des logiciels statistiques comme R ou SAS sont souvent utilisés pour l'analyse."
}
},
{
"@type": "Question",
"name": "Quelles données sont nécessaires pour l'analyse ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des données chronologiques avant et après l'intervention sont essentielles."
}
},
{
"@type": "Question",
"name": "Comment évaluer la validité des résultats ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il faut vérifier la robustesse des résultats par des tests de sensibilité."
}
},
{
"@type": "Question",
"name": "Quels biais peuvent affecter l'analyse ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les biais de sélection et de mesure peuvent fausser les résultats."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent être analysés ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fréquence des hospitalisations ou des décès peuvent être mesurés."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils après une intervention ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse peut montrer une diminution ou une augmentation des symptômes post-intervention."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer des symptômes subjectifs ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des échelles de mesure peuvent évaluer des symptômes subjectifs comme la douleur."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils influencés par des facteurs externes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs comme la saisonnalité peuvent influencer les symptômes observés."
}
},
{
"@type": "Question",
"name": "Comment les symptômes sont-ils collectés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être collectés par des enquêtes, des dossiers médicaux ou des observations."
}
},
{
"@type": "Question",
"name": "Comment l'analyse aide-t-elle à la prévention ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet d'évaluer l'impact des programmes de prévention sur des résultats de santé."
}
},
{
"@type": "Question",
"name": "Quels programmes peuvent être analysés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes de vaccination, de dépistage ou d'éducation à la santé peuvent être évalués."
}
},
{
"@type": "Question",
"name": "Comment mesurer l'impact d'une campagne de prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'impact est mesuré par des changements dans les comportements ou les taux de maladies."
}
},
{
"@type": "Question",
"name": "Quels indicateurs de prévention sont pertinents ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des indicateurs comme le taux d'incidence ou de prévalence des maladies sont pertinents."
}
},
{
"@type": "Question",
"name": "Peut-on évaluer des interventions non médicales ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des interventions comme des changements de politique ou d'environnement peuvent être analysées."
}
},
{
"@type": "Question",
"name": "Quels traitements peuvent être évalués par cette méthode ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements médicaux, chirurgicaux ou comportementaux peuvent être analysés."
}
},
{
"@type": "Question",
"name": "Comment mesurer l'efficacité d'un traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est mesurée par des changements dans les résultats cliniques après l'intervention."
}
},
{
"@type": "Question",
"name": "Peut-on comparer plusieurs traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'analyse peut comparer l'impact de différents traitements sur les mêmes résultats."
}
},
{
"@type": "Question",
"name": "Quels indicateurs de traitement sont utilisés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des indicateurs comme le taux de guérison ou la réduction des symptômes sont utilisés."
}
},
{
"@type": "Question",
"name": "Comment les effets secondaires sont-ils pris en compte ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires doivent être mesurés et analysés pour évaluer la sécurité du traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent être analysées ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme les infections ou les effets indésirables des traitements peuvent être évaluées."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles mesurées ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles sont mesurées par des taux d'incidence ou des événements indésirables rapportés."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles influencées par le temps ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent varier selon la période de suivi après l'intervention."
}
},
{
"@type": "Question",
"name": "Peut-on prédire des complications futures ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse peut aider à prédire des complications en fonction des tendances observées."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications identifiées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des stratégies de gestion doivent être mises en place pour minimiser les complications."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque peuvent être analysés ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs comme l'âge, le sexe, et les comorbidités peuvent être évalués."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque influencent-ils les résultats ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent modifier l'impact d'une intervention sur les résultats de santé observés."
}
},
{
"@type": "Question",
"name": "Peut-on identifier des facteurs de risque modifiables ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'analyse peut aider à identifier des facteurs de risque qui peuvent être modifiés."
}
},
{
"@type": "Question",
"name": "Comment les facteurs de risque sont-ils mesurés ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils sont mesurés par des questionnaires, des dossiers médicaux ou des études épidémiologiques."
}
},
{
"@type": "Question",
"name": "Les facteurs de risque changent-ils avec le temps ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les facteurs de risque peuvent évoluer en fonction des changements environnementaux ou sociaux."
}
}
]
}
]
}
Network meta-analysis has been an essential methodology of systematic reviews for comparative effectiveness research. The restricted maximum likelihood (REML) method is one of the current standard inf...
With recent advancements in bronchoscopic procedures, data on the best modality to sample peripheral pulmonary lesions (PPLs) is lacking, especially comparing bronchoscopy with computed tomography-gui...
We performed a meta-analysis, pairwise meta-analysis and network meta-analysis on studies reporting diagnostic yield and complications with the use of CT-TBNA, radial endobronchial ultrasound (rEBUS),...
We included 363 studies. The overall pooled diagnostic yield was 78.1%, the highest with CT-TBNA (88.9%), followed by RAB (84.8%) and the least with rEBUS (72%). In the pairwise meta-analysis, only rE...
Although CT-TBNA is the most effective approach to sample PPLs, RAB has a comparable diagnostic yield with a lesser complication rate. Further prospective studies are needed comparing CT-TBNA and RAB....
Eczema (atopic dermatitis) is the most burdensome skin condition worldwide and cannot currently be prevented or cured. Topical anti-inflammatory treatments are used to control eczema symptoms, but the...
To compare and rank the efficacy and safety of topical anti-inflammatory treatments for people with eczema using a network meta-analysis....
We searched the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries on 29 June 2023, and checked the reference lists of included studies....
We included within-participant or between-participant randomised controlled trials (RCTs) in people of any age with eczema of any severity, but excluded trials in clinically infected eczema, seborrhoe...
We used standard Cochrane methods. Primary outcomes were patient-reported eczema symptoms, clinician-reported eczema signs and investigator global assessment. Secondary outcomes were health-related qu...
We included 291 studies involving 45,846 participants with the full spectrum of eczema severity, mainly conducted in high-income countries in secondary care settings. Most studies included adults, wit...
Potent TCS, JAK inhibitors and tacrolimus 0.1% were consistently ranked as amongst the most effective topical anti-inflammatory treatments for eczema and PDE-4 inhibitors as amongst the least effectiv...
Despite considerable improvement in outcomes for preterm infants, rates of bronchopulmonary dysplasia (BPD) remain high, affecting an estimated 33% of very low birthweight infants, with corresponding ...
To determine whether differences in efficacy and safety exist between high-dose dexamethasone, moderate-dose dexamethasone, low-dose dexamethasone, hydrocortisone, and placebo in the prevention of BPD...
We searched the Cochrane Library for all systematic reviews of systemic corticosteroids for the prevention of BPD and searched for completed and ongoing studies in the following databases in January 2...
We included randomized controlled trials (RCTs) in preterm infants (< 37 weeks' gestation) at risk for BPD that evaluated systemic corticosteroids (high-dose [≥ 4 mg/kg cumulative dose] dexamethasone,...
Our main information sources were the systematic reviews, with reference to the original manuscript only for data not included in these reviews. Teams of two paired review authors independently perfor...
We included 59 studies, involving 6441 infants, in our analyses. Only six of the included studies provided direct comparisons between any of the treatment (dexamethasone or hydrocortisone) groups, for...
Low-dose dexamethasone increased the risk for cerebral palsy (RR 1.92, 95% CI 1.12 to 3.28; moderate-certainty evidence) compared with control. Hydrocortisone may decrease the risk of major neurosenso...
No effect was observed for the outcomes of major neurosensory disability or cerebral palsy. The evidence for the primary outcomes was of overall low certainty, with notable deductions for imprecision ...
While early treatment with moderate-dose dexamethasone or late treatment with high-dose dexamethasone may lead to the best effects for survival without BPD, the certainty of the evidence is low. There...
Severely calcified coronary stenoses are difficult to treat with percutaneous coronary interventions. The presence of severe calcifications complicates lesion preparation, advancement of stents and ac...
We will conduct a systematic review of randomised trials enrolling patients with calcified coronary artery disease undergoing percutaneous coronary intervention. We will investigate any percutaneous t...
No ethics approval is required for this study. The results will be published in a peer-reviewed journal in this field....
CRD42021226034....
Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects mainly young adults (two to three times more frequently in women than in men) and causes significant disability ...
To compare adverse effects of immunotherapies for people with MS or clinically isolated syndrome (CIS), and to rank these treatments according to their relative risks of adverse effects through networ...
We searched CENTRAL, PubMed, Embase, two other databases and trials registers up to March 2022, together with reference checking and citation searching to identify additional studies....
We included participants 18 years of age or older with a diagnosis of MS or CIS, according to any accepted diagnostic criteria, who were included in randomized controlled trials (RCTs) that examined o...
We used standard Cochrane methods for data extraction and pairwise meta-analyses. For NMAs, we used the netmeta suite of commands in R to fit random-effects NMAs assuming a common between-study varian...
This NMA included 123 trials with 57,682 participants...
We found mostly low and very low-certainty evidence that drugs used to treat MS may not increase SAEs, but may increase withdrawals compared with placebo. The results suggest that there is no importan...
A comprehensive network meta-analysis comparing the effects of individual sodium-glucose cotransporter 2 (SGLT2) inhibitors on patients with and without comorbidities including diabetes mellitus (DM),...
We searched PubMed, Embase, Cochrane, and ClinicalTrials.gov for randomized controlled trials up to March 28, 2023. Network meta-analysis using a random-effects model was conducted to calculate risk r...
A total of fourteen trials with 75,334 patients were analyzed. Among these, 40,956 had taken SGLT2 inhibitors and 34,378 had not. One of the main results with particular findings was empagliflozin use...
Our network meta-analysis revealed that empagliflozin users with diabetes experienced a lower risk of dying from any cause than those using dapagliflozin. Additionally, canagliflozin users demonstrate...
PROSPERO [CRD42022361906]....
Multiple randomized controlled trials, each comparing a subset of competing interventions, can be synthesized by means of a network meta-analysis to estimate relative treatment effects between all int...
Surgical treatment of complete rectal prolapse can be undertaken via an abdominal or a perineal approach. The present network meta-analysis aimed to compare the outcomes of different abdominal and per...
A PRISMA-compliant systematic review of PubMed, Scopus, and Web of Science was conducted. Randomized clinical trials comparing two or more procedures for the treatment of complete rectal prolapse were...
Nine randomized controlled trials with 728 patients were included. The follow-up ranged between 12 and 47 months. Posterior mesh rectopexy had significantly lower odds of recurrence than did the Altem...
Posterior mesh rectopexy ranked best with the lowest recurrence while perineal procedures ranked worst with the highest recurrence rates....
Several vaccines showed a good safety profile and significant efficacy against COVID-19. Moreover, in the absence of direct head to head comparison between COVID-19 vaccines, a network meta-analysis t...
Databases PubMed, CENTRAL, medRxiv, and clinicaltrials.gov were searched. Studies were included if they were placebo-controlled clinical trials and reported the safety profile and/or effectiveness of ...
Forty-nine clinical trials that included 421,173 participants and assessed 28 vaccines were included in this network meta-analysis. The network meta-analysis showed that Pfizer is the most effective i...
We found that almost all of the vaccines included in this study crossed the threshold of 50% efficacy. However, some of them did not reach the previously mentioned threshold against the B.1.351 varian...
